National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

cannabis-based oromucosal spray GW-1000-02
An herbal preparation containing a defined quantity of specific cannabinoids formulated for oromucosal spray administration with potential analgesic activity. Cannabis-based oromucosal spray GW-1000-02 contains a standardized extract of tetrahydrocannabinol (THC), the non-psychoactive cannabinoid cannabidiol (CBD), other minor cannabinoids, flavonoids, and terpenes from two cannabis plant varieties. Cannabinoids interact with G protein-coupled cannabinoid 1 (CB1) receptors in the central nervous system, resulting in analgesic, euphoric, and anticonvulsive effects. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Foreign brand name:Sativex
Code name:GW-1000-02



Previous:Camptosar, canarypox-hIL-12 melanoma vaccine, Cancidas, candesartan cilexetil, canertinib dihydrochloride
Next:Canvaxin, capecitabine, Capoten, captopril, caracemide

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov